循环网膜素升高与糖尿病患者原发性心血管事件风险增加相关
本研究基于德国ESTHER队列中933例无心血管事件史的糖尿病患者,随访14年,采用ELISA测定基线血清网膜素浓度,Cox回归分析其与心血管复合终点等的关系。结果显示,校正多种心血管危险因素后,网膜素最高三分位组与最低三分位组相比,心血管复合终点、卒中及心血管死亡风险显著增加。
要点
- 糖尿病患者中,血清网膜素最高三分位组心血管复合终点风险显著升高(HR 1.63,95%CI 1.15-2.32)。
- 网膜素与卒中风险(HR 2.05,95%CI 1.17-3.58)及心血管死亡风险(HR 1.72,95%CI 1.04-2.83)呈正相关。
- 该关联独立于年龄、性别、BMI、代谢及生活方式因素和用药,且额外校正脂联素后几乎不变。
核心结论
- 在糖尿病患者中,较高的血清网膜素浓度与心血管事件风险增加独立相关。
研究设计与样本
- 前瞻性队列研究,基于德国ESTHER队列中933例50-75岁、无既往心血管事件的糖尿病患者,基线ELISA测血清网膜素,随访14年。
主要发现
- 随访期间228例发生主要心血管事件(心肌梗死、卒中或心血管死亡)。
- 校正年龄、性别、BMI、代谢和生活方式因素及用药后,网膜素第2、3三分位 vs 第1三分位的心血管复合终点HR分别为1.24(95%CI 0.86-1.79)和1.63(95%CI 1.15-2.32),ptrend=0.005。
- 卒中的HR分别为1.40(95%CI 0.78-2.53)和2.05(95%CI 1.17-3.58),ptrend=0.010。
- 心血管死亡的HR分别为1.43(95%CI 0.85-2.40)和1.72(95%CI 1.04-2.83),ptrend=0.040。
- 心肌梗死的HR分别为1.39(95%CI 0.78-2.47)和1.71(95%CI 0.98-2.99),ptrend=0.065。
临床怎么用
- 在糖尿病患者心血管风险分层中,可考虑关注血清网膜素水平,但尚不能作为独立干预靶点。
局限性
- 研究基于德国ESTHER队列,外推性需谨慎。
- 观察性设计不能确定因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Higher concentrations of the adipokine omentin are associated with lower levels of cardiometabolic risk factors in experimental and cross-sectional studies, but with higher risk of type 2 diabetes and cardiovascular diseases in population-based cohort studies. However, it is unknown whether high omentin concentrations are associated with increased risk of cardiovascular events in people with established diabetes. Therefore, the present study investigated the association between serum omentin concentrations and the risk of cardiovascular events in individuals with diabetes. METHODS: This prospective study was based on participants of the German ESTHER cohort with diabetes and without previous cardiovascular event. The ESTHER cohort consists of individuals aged 50-75 years at baseline who were recruited by their general practitioners. After exclusion of individuals with serum C-reactive protein ≥10 mg/l (≥95.24 nmol/l), the final analysis population consisted of 933 individuals. At baseline, serum omentin concentrations were measured by ELISA. Cox regression models were fitted to estimate HRs and their corresponding 95% CIs for associations of omentin tertiles with a composite endpoint of cardiovascular events and separately with incident myocardial infarction, stroke and cardiovascular death. RESULTS: During 14 years of follow-up, 228 individuals experienced a primary cardiovascular event (myocardial infarction, stroke or cardiovascular death). After comprehensive adjustment for age, sex, BMI, metabolic and lifestyle factors and medication use, HRs (95% CIs) for the 2nd and 3rd tertile of omentin compared with the 1st tertile were: 1.24 (95% CI 0.86, 1.79) and 1.63 (1.15, 2.32) (ptrend = 0.005) for the composite cardiovascular endpoint; 1.39 (0.78, 2.47) and 1.71 (0.98, 2.99) (ptrend = 0.065) for incident myocardial infarction; 1.40 (0.78, 2.53) and 2.05 (1.17, 3.58) (ptrend = 0.010) for incident stroke; and 1.43 (0.85, 2.40) and 1.72 (1.04, 2.83) (ptrend = 0.040) for cardiovascular death. Effect estimates and p values were almost unaltered after additional adjustment for adiponectin. CONCLUSIONS/INTERPRETATION: Higher omentin concentrations are associated with an increased risk for cardiovascular events in individuals with diabetes after adjustment for multiple cardiovascular risk factors. Given data from preclinical studies, it appears possible that this association reflects a compensatory, but insufficient upregulation of omentin concentrations as a response to stimuli that increase cardiovascular risk.
引用
- Niersmann C, Carstensen-Kirberg M, Maalmi H, et al. Higher circulating omentin is associated with increased risk of primary cardiovascular events in individuals with diabetes. Diabetologia. 2019. PMID: 31705160. doi:10.1007/s00125-019-05017-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。